Quarterly report pursuant to Section 13 or 15(d)

Condensed Balance Sheets

v2.4.0.6
Condensed Balance Sheets (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2012
Dec. 31, 2011
Assets    
Cash $ 2,308 $ 5,406
Receivables 3,531 3,720
Prepaid expenses and other current assets 898 836
Total current assets 6,737 9,962
Property and equipment, net 772 255
Total assets 7,509 10,217
Liabilities and Stockholders' Deficit    
Accounts payable 4,060 4,789
Accrued clinical trials expenses 1,308 161
Other accrued liabilities 519 173
Total current liabilities 5,887 5,123
Warrant liability 3,627 3,611
Royalty liability 9,476 9,309
Long-term debt, net of discount 12,209 12,253
Total liabilities 31,199 30,296
Commitments and contingencies      
Stockholders' deficit    
Common stock, at amounts paid-in 256,436 256,436
Additional paid-in capital 19,985 18,433
Accumulated deficit (300,111) (294,948)
Total stockholders' deficit (23,690) (20,079)
Total liabilities and stockholders' deficit $ 7,509 $ 10,217